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Summary: The diagnostic performance of the haematology analysers, Technicon Hl, Sysmex NE 8000, Coulter
STKS and Sequoia Cell Dyn 3000 was determined by comparing their results for automated differential
counting with the result obtained for 400 cells by the manual microscopic method. These comparative studies
were performed on a group of adults, containing both normal individuals (n = 150) and those affected by
various pathologies (n = 113). The number of morphologically false negatives is low for all the systems (from
1.8% for the Cell Dyn 3000 to 6.2% for the NE 8000), while the number of distributionally false negatives
was slightly higher (from 4.4% for the Cell Dyn 3000 to 7% for the HI and NE 8000). The morphological
flags, though useful for improving the diagnostic performance of the instruments, show a rather modest
sensitivity when taken individually: immature granulocytes/bands from 71% for the STKS to 43% for the
NE 8000; blasts from 66.6% for the HI to 53.3% for the STKS, atypical lymphocytes from 59% for the HI
to 13.6% for the NE 8000; erythroblasts from 42.8% for the STKS to 7% for the NE 8000.
Introduction
In recent years many haematological analysers have
been introduced into clinical laboratories, which, in
addition to a complete cellular blood count, are cap-
able of providing some new erythrocyte and platelet
indices (red cell distribution width, mean platelet vol-
ume, platelet distribution width, plateletcrit) and the
differential leukocyte count on five or more cell types.
Moreover, these instruments generate quantitative or
morphological flags to indicate abnormalities. The
advantages of the automated differential count over
the manual microscopic count using 100 or 200 cells
are a greater analytical precision (1 — 3) (the differ-
ential leukocyte count is performed by counting
thousands of cells instead of hundreds and is accom-
panied by excellent accuracy, at least for neutrophils,
lymphocytes and eosinophils (4—8)), and a reduction
in costs and turnaround time, due to the high through-
put. The simultaneous production of "scattergrams"
relative to the leukocyte population in association
with interpretative flags is also an aid to diagnosis
(9 — 11). The usefulness of the generalized differential
count, even when automated, is not universally ac-
knowledged; some authors maintain that when the
complete cellular blood count is normal, nor or very
few clinical advantages are to be gained from the
differential leukocyte count (12). According to other
authors, the usefulness of the differential leukocyte
count is limited to the follow-up of acute infectious
processes, of haematology disorders, of allergic con-
ditions, or to the monitoring of therapies with hae-
matological side-effects, rather than being seen as a
screening device (13, 14). We must not forget the
initial distrust shown by clinicians towards the intro-
duction of the automated differential count, in favour
of the microscopic examination, although the latter's
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inaccuracy and imprecision are well-known (15). The
purpose of the present study is to evaluate the diag-
nostic performance (the power to distinguish between
pathological and normal conditions) of the differen-
tial leukocyte count as performed on four modern
haematology analysers (Technicon Hl, Sysmex NE
8000, Coulter STKS, Sequoia Cell Dyn 3000), consid-
ering the standard NCCLS H20-T (16) as a guideline
and analysing simultaneously blood samples taken
from the same group of patients. Since these instru-
ments provide flags of morphological suspect: left
shift or bands, immature granulocytes, immature
granulocytes/bands, blasts, atypical lymph or variant,
erythroblasts, it was decided to evaluate the sensitiv-
ity, the specificity, the predictive value and the diag-
nostic efficiency of each flag (17) with reference to a
group of patients with a high prevalence of disease.
Materials and Methods
Ins t ruments
The evaluation was performed in the Biochemistry and Hae-
matology Laboratory of Santa Chiara Hospital in Trento (It-
aly), where 500 complete cellular blood counts and 300 differ-
ential leukocyte counts are carried out daily on both in-patients
and out-patients. The instruments tested during a two-week
period, were Technicon HI (HI) (Technicon Instruments Cor-
poration, Tarrytown, NY), Sysmex NE 8000 (NE 8000) (Toa
Medical Corporation, Kobe, Japan), Coulter STKS (STKS)
(Coulter Electronics Hialeah, FL), Cell Dyn 3000 (CD 3000)
(Sequoia Turner, Mountain View, CA). All the instruments
provide a number of blood count quantities and a five- (NE
8000, STKS, CD 3000) or six- (HI) population leukocyte dif-
ferential count. The analysers also produce a scattergram for
the distribution of the leukocyte populations and a series of
morphological and distributional flags. NE 8000, HI and STKS
were equipped with an automatic sampler, whereas the CD
3000 needs manual sampling and a shaking mixer; all the
instruments aspirated close-vial blood samples. The analysers
were calibrated according to the manufacturers' guidelines and
were constantly monitored by an internal quality control system
(trilevel commercial blood, inserted three times in the daily
routine; moving Bull mean on the analysed samples).
Patients
Blood samples were analysed from 263 subjects of both sexes,
aged 18 to 70, 150 of which constituted the control group and
were selected according to NCCLS H20-T recommendations.
The other 113 patients, who constituted the group with the
high prevalence of haematological or inflammatory diseases
and whose clinical conditions are specified in table 1, were
utilized in the diagnostic performance study. All samples were
collected with the aware consent of the donors. Each sample
was distributed at the moment of collection (by venipuncture)
into five 3 ml KsEDTA closed tubes (Vacutainer, Becton Dick-
inson Corporation, Mountain View, CA), which afterwards
were randomly assigned to each one of the four instruments
and to the reference system. All the specimens were kept at
room temperature (18—20 °C) and tested between 30 minutes
and four hours after collection. Four blood smears were pre-
pared from each sample within two hours of collection. Two
of the four smears were randomly assigned to two operators
for the microscopic differential count. The blood smears were
fixed and stained using the Wright method (Hema-Tek, Ames
automatic stain, Miles Ltd, Slough, England).
Tab. 1. Specimen types for the diagnostic performance study.
Clinical condition Number
of samples
Acute inflammation
— Bacterial infections 17
— Tissue necrosis, surgery 11
— Viral infections 12
Metastatic carcinomas 6
Haematologic disorders
— Acute leukaemias 9
— Chronic myeloproliferative disorders 7
— Myelodisplastic syndromes 3
— Chronic lymphoproliferative disorders 8
— Aplastic anaemia 4
Healthy subjects 36
Total 113
Drafting of the study
The reference intervals were established on the 150 subjects
that made up the control group. For each sample the differential
leukocyte count was determined using both the reference
method (an average of two 200-cell manual counts on two
different smears performed by two morphology experts) and
each one of the four evaluated instruments (average of differ-
ential counts on two replicates). Frequency distributions were
created for each leukocyte population for each used method
(reference and tests) and, after removal of outliers (±3 SD),
the central 95 percentile of the distributions was determined.
The results obtained from the group of 113 patients were
classified as follows: normal, if values of each subpopulation
ranked between 2.5 and 97.5 percentile for each system and if
no morphological abnormality was present; with distributional
abnormality if at least one leukocyte population exceeded the
central 95 percentile limits and no morphological abnormality
was present. In order to detect the presence of a morphological
abnormality in the reference method, the arbitrary limits shown
in table 2 were chosen; lower values in percentage of bands,
metamyelocytes and myelocytes were added to neutrophils,
while atypical lymphocytes (variant) were added to the lym-
phocytes. A sample was considered morphologically abnormal,
according to the results from the tested instruments, if at least
one of the following criteria applied:
a) production of one or more morphological flags related to
nucleated cells,
b)incomplete differential leukocyte count,
c) flags on the count or count over-range (data exceed the linear
or printable range for leukocytes).
Tab. 2. Criteria for the evaluation of the reference differential
method. The reference differential was classified as mor-
phologically abnormal if one of the following criteria
were met.
Bands
Immature granulocytes
— metamyelocytes
— myelocytes
— myelo + metamyelocytes
Blasts
Atypical lymphocytes
Erythroblasts
4%
3%
2%
3%
0%
4%
1%
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Tab. 3. Comparison of flags
Reference
Bands
Immature granulocytes
Blasts
Atypical lymphocytes
Erythroblasts*
—
from different methods
Technicon HI
left shift
IG
blasts
atypical
NRBC
LUCs (> 4%)
—
(reference and tests).
Sysmex NE 8000
left shift
imm. grans
blasts
atypical lymphs.
NRBC
** _
—
Coulter STKS
imm. grans/bands
blasts
variant lymphs.
NRBC
—
Sequoia CD 3000
IG/bands
NRBC
diff/alert
* NRBC = nucleated red blood cells
** LUCS = large unstained cells
For Technicon HI the sixth population (large unstained cells)
was considered to be an index of morphological abnormality
when its value was > 4%; lower values were added to the
lymphocytes. Table 3 gives a list of the morphological flags
considered for the four instruments. It can be seen that not all
the analysers show the same flags. In the Cell Dyn 3000 the
generic wording "Diff Alert" is produced by the software ver-
sion (rev. 1.18) to the signal both distributional and morpho-
logical anomalies; in the present work it was always used as a
morphological flag. If both distributional and morphological
abnormalities were present, the sample was classified as abnor-
mal only for morphology, in agreement with the NCCLS stan-
dard H20-T. The results were then classified for each method
(reference and tests) as normal, abnormal for distribution, and
abnormal for morphology. Then the preliminary analysis was
carried out, comparing the average of the two counts from the
reference method with the first count of each analyser. In cases
of morphological or distributional disagreements, an arbitra-
tion by consent was carried out by four morphology experts,
using the four smears previously prepared and counting of 800
cells. The subsequent phase of the study consisted of the eval-
uation of sensitivity, specificity, predictive value and diagnostic
efficiency (17) for the single morphological flags relative to the
nucleated cells. The analytical sensitivity of the same flags was
then evaluated, comparing the percentage of the corresponding
cells obtained with the reference method (eye-count differential)
in the presence or absence of the instrumental flag.
Results
The reference intervals for the five leukocyte popu-
lations in each method (reference and tests) are shown
in table 4. The intervals are quite superimposable both
among the various instruments and between these and
the reference method; the most significant differences
are the higher value for the neutrophils related to the
2.5 percentile, and the lower value for the lymphocytes
related to the 97.5 percentile on the NE 8000, and the
definitely higher value for the basophils related to the
97.5 percentile in the STKS in comparison with the
other systems. The definitive results (after the arbi-
tration) for the 113 patients who were classified as
normal, abnormal for distribution and abnormal for
morphology by each of the evaluated methods, are
shown in table 5. Table 6 shows the summarising data
on the diagnostic performance. It can be noticed that,
on the whole, there were eight distributional false
negatives with HI (7%), eight with NE 8000 (7%),
six with STKS (5.3%) and five with CD 3000 (4.4%);
Tab. 4. Determination of reference intervals by reference and test methods.
Quantity Reference Technicon HI Sysmex NE 8000 Coulter STKS
Tab. 5. Comparison of the test methods with the reference method.
Sequoia CD 3000
Neutrophils (%)
Lymphocytes (%)
Monocytes (%)
Eosinophils (%)
Basophils (%)
41.2-75.0
17.7-49.2
3.0- 9.0
0.0- 7.8
0.0- 1.5
41.4-74.0
16.8-48.0
3.9- 9.4
0.4- 7.9
0.3- 1.7
45.3-74.7
16.7-44.3
2.9- 9.0
0.5- 7.3
0.3- 1.6
41.3-72.1
19.8-49.1
3.5- 8.3
0.5- 7.9
0.2- 2.6
40.3-71.6
18.8-48.4
1.8-10.3
1.4- 8.6
0.4- 1.6
Reference Technicon HI Sysmex NE 8000 Coulter STKS
N D M N D M N M
N = normal; D = distributionally abnormal; M = morphologically abnormal
Sequoia CD 3000
N D M
N
D
M
32
8
3
6
10
6
2
5
41
32
8
6
6
15
17
2
0
27
34
6
4
4
13
9
2
4
37
33
5
2
4
12
9
3
6
39
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table 7 shows in detail the failed distributional ab-
normalities in comparison with the reference method
for each instrument. There were three morphological
false negatives with HI (2.6%), i.e. those samples
that were classified as normal with the test method,
even though they had morphological abnormalities
when tested with the reference method: two patients
with atypical lymphocytes (respectively 6% and 10%)
and affected by acute viral infection, and one patient
with bands (7%), who had recently undergone an
surgical trauma. Then there were six morphological
false negatives with NE 8000 (5.3%): three patients
with atypical lymphocytes, two of which were affected
by acute viral pathology (with 6% and 8% of variant);
one patient, who was being treated for acute lym-
phoblastic leukaemia at present in complete remis-
sion, with atypical lymphocytes (5%); one subject
with myeloid blasts (< 1%) arid affected by refrac-
tory anaemia with excess of blasts; one patient with
metamyelocytes and bands (6%) and affected by acute
bacterial infection; finally one patient from a general
surgical ward, with bands (7%). Four morphological
false negatives were found with STKS (3.5%): two
patients with atypical lymphocytes (8% and 10%)
and affected by acute viral infection; one patient with
metamyelocytes and bands (6%) and affected by acute
bacterial infection, and one patient with bands (7%)
from a general surgical ward. Two morphological false
Tab. 6. Final classification of diagnostic performance*.
Technicon HI
Samples %
Sysmex NE 8000 Coulter STKS
Samples % Samples %
Sequoia CD 3000
Samples %
Total agreement
Partial agreement
False normal distribution
False normal morphology
83/113
11/113
8/113
3/113
73.4
9.7
7.0
2.6
74/113
17/113
8/113
6/113
65.5
15.0
7.0
5.3
84/113
13/113
6/113
4/113
74.3
11.5
5.3
3.5
84/113
15/113
5/113
2/113
74.3
13.2
4.4
1.8
* The agreement is partial when a different type of abnormality (distributional vs morphological or morphological vs distribu-
tional) is found by reference and test methods.
Tab. 7. Analysis of false normal distribution results. Number of samples with abnormalities missed by test methods.
Technicon HI Sysmex NE 8000 Coulter STKS Sequoia CD 3000
Increased neutrophils
Decreased neutrophils
Increased lymphocytes
Decreased lymphocytes
Increased monocytes
Increased basophils
Total
2
1
2
—
2
1
8
2
2
1
1
1
1
8
1
—
1
1
2
1
6
—
1
1
2
1
5
Tab. 8. Reliability and frequency of individual flags as detectors of specific abnormalities (samples = 113)*.
Flag Refer- Technicon HI Sysmex NE 8000 Coulter STKS Sequoia CD 3000
Bands or left shift
Immature granulocytes
and/or bands
Immature granulocytes
Blasts
Atypical lymphocytes
cnoe
10**
28
22**
15
22
TP
3
14
6
10
13
FP
17
6
2
8
6
FN
7
14
16
5
9
TP
2
12
8
9
3
FP
4
7
7
3
5
FN
8
16
14
6
19
TP
—
20
—
8
8
FP
—
9
—
7
8
FN TP
^ —
8 16
_. — ·
7 ·:-
14
FP FN
— _
10 12
— —
— —
— _.
or variant
Erythroblasts (NRBC)* 14 11 10 13 12
TP = true positive; FP = false positive; FN = false negative.
* Each sample can present one or more flags.
** Four samples contemporaneously presents both "bands" and "IG" flag.
*** Nucleated red blood cells
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negatives were produced with CD 3000 (1.8%): both
patients with atypical lymphocytes (6% and 8%) and
affected by acute viral infection. In the 150 subjects
who made up the control group, the tested analysers
produced morphological flags for nucleated cells,
which were not confirmed either by the clinical study
carried out on the donors or by the microscopic
revision on the four smears. The flags were distributed
as follows: two (1.3%) on the HI, both atypical
lymphocytes and large unstained cells > 4%; five
(3.3%) on the NE 8000, four atypical lymph and one
atypical lymphocytes and blasts; two (1.3%) on the
STKS, both erythroblasts; twenty-four (16%) on the
CD 3000, fifteen diff alert and nine diff alert +
immature granulocytes/bands. Table 8 compares the
morphological flags identified by the different ana-
lysers on the same sample relative to the 61 subjects
(all belonging to the patient group) who show mor-
phological abnormalities in at least one of the meth-
ods, underlining that in the same sample more than
one flag could co-exist. The estimate of sensitivity,
specificity, predictive value of the positive and nega-
tive tests and of the diagnostic efficiency of the flags
was referred to the group of 113 patients; the results
are shown in table 9. The analytical sensitivity of the
flags was analysed, comparing both the percentage
representation and the absolute concentration [con-
centration = percent χ leukocytes (109/1)] of the
atypical cells detected by the reference method when
the instrument produced a relevant flag; the compar-
ative results are shown in figures la, b, c, d. For the
flags "left shift" and "IG" (immature granulocytes)
two instruments produce a single flag (HI and NE
8000), whereas others produce a mixed flag "IG/
bands" (STKS and CD 3000). For the comparability
of results, a "mixed" flag was also individualized for
HI and NE 8000, by considering both the "left shift"
and "IG" flags to represent "immature granulocytes/
bands", irrespective of whether they were produced
individually or together.
Discussion
In the control group, the reference intervals for the
five leukocyte populations are similar to others pub-
lished for healthy adult populations (18, 19), and are
quite superimppsable between the reference method
and the various tested instruments. Slight decreases
were observed for the upper limit of neutrophils on
the STKS (-2.9%) and CD 3000 (-3.4%), and of
lymphocytes on the NE 8000 (—4.9%), and increases
for the lower limit of neutrophils on the NE 8000
(+ 4.1%), relative to the reference method. Another
relevant observation is that the upper limit for baso-
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Fig. l. Comparative results for the analytical sensitivity of individual flags
x-axis: flag present (+) or absent (—), y-axis: percentage of cells found by the manual method;
(a) blasts, (b) immature granulocytes/bands, (c) atypical lymphocytes, (d) erythroblasts.
phils on the STKS is notably higher than for both the
reference method (+1.1%) and the other analysers
(from + 0.9% to + 1 %). In this group the instru-
ments produced a low percentage of morphological
false positives on the HI and STKS (1.3%), a slightly
higher percentage on the NE 8000 (3.3%), but in a
very high one on the CD 3000 (16%). If this last
instrument was used routinely to analyse populations
with a high prevalence of healthy subjects, it would
therefore involve, if compared with the other analy-
sers, a considerable number of microscopic controls,
which would not be justified by the clinical conditions
of the patient. The study of the diagnostic perform-
ance of the differential leukocyte count, using the 113
subjects, shows a good global sensitivity with a very
low number of morphological false negatives. Al-
though the distributional false negatives were more
numerous, this was of no consequence, because the
percentage difference in the various populations was
never clinically significant. The agreement between
reference method and tests is good: 65.5% (NE 8000),
73.4% (HI), and 74.3% (STKS and CD 3000); the
lower agreement observed for the NE 8000 is due to
the greater number of samples with morphological
abnormalities, not classified as such, but only as a
distributional abnormality. The analysis of the flags
show that whenever they are used as a generic alarm
to direct the operator to perform a microscopic con-
trol (as suggested by the manufacturers), they con-
tribute to a remarkable improvement in the diagnostic
performance of the instruments. If. we consider the
flags as detectors of specific abnormalities, however,
they show a modest sensitivity:
a) the sensitivity for detecting, blasts decreases in the
order: HI > NE 8000 >' STKS. This flag, al-
though in all the analysers, tends to become more
sensitive as the concentration of blasts increases,
Eur. J. Clin. Chem. CHn. Biochem. / Vol. 31,1993 / No. 4
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it correlates better with the percentage distribution
than with the absolute value (count per litre). HI
shows high analytical sensitivity for the myeloid
blasts (no false negatives for values above 1%);
whereas the false negatives for lymphoid blasts
contained, as determined with the reference
method, 5%, 2% and 0.5% blasts. For the other
analysers, the variable distribution of false nega-
tives diversifies their response: NE 8000 gave five
false negatives for samples containing myeloid
blasts, two of these cases containing 17% and 18%
blasts; and only one false negative for lymphoid
blasts (0.5% with the reference method). STKS
reported five cases of false negatives for myeloid
blasts (one case with 40% of blasts) and two false
negatives for lymphoid blasts;
b) the flags of immature granulocytes or left shift,
considered individually (HI and NE 8000), show
a very low sensitivity (values between 30% of HI
and 20% of NE 8000). When they were considered
as "IG/bands" flags, the sensitivity decreased in
the order: STKS > CD 3000 > HI > NE 8000.
This flag also tends to become more sensitive with
increasing concentrations of the young or imma-
ture granulocytes, with the exception of NE 8000,
which presents two false negatives for reference
method values above 15%. As far as the bands are
concerned, the reference interval for healthy sub-
jects (obtained through microscope observations)
shows a very varied upper limit in the various
published studies, ranging from 6% (20) to 6.75%
(19) to 8.5% (19) to 10% (21, 22), to 11% (23),
up to 12% (24). The cut-off values used in previous
researches aimed at evaluating the instrumental
flags were also varied, ranging from 5% to 10%
(4), to 8% (5), to 11% (23). In the present study,
not all the instruments were capable of separating
the flag for left shift or bands from that for im-
mature granulocytes. In order to evaluate the an-
alytical sensitivity of the flag (which in this case
becomes immature granulocytes/bands), the sum
of the percentages of bands and of immature gran-
ulocytes detected with the microscope was there-
fore used as a reference method. In this case the
microscope cut-off (bands + metamyelocytes) be-
comes 7% and agrees with some of the previously
mentioned studies. The cut-off of the instrument
that shows the greatest analytical sensitivity
(STKS) is about 7%, so that only this instrument
could have a flag response sufficiently sensitive to
replace microscopic analysis. For the other ana-
lysers our results agree with those of some authors
(4, 25), but are slighly less optimistic than others
with reference to HI (5, 23, 26) or to NE 8000 (5);
c) the flag for atypical lymphocytes shows a sensitiv-
ity in the order: HI > STKS > NE 8000; on the
HI the flag correlates better with the percentage
value rather than with the absolute concentration.
As regards the other two instruments, the distri-
bution of the results does not show a precise cor-
relation with the percentage or with the concentra-
tion of the variants revealed with the reference
method;
d) the flag for the presence of erythroblasts is not
very reliable in any of the instruments (sensitivity
between 42.8% for the STKS and 7% for the NE
8000).
When these analysers are used in hospital laborato-
ries, which give simultaneous access to normal sub-
jects and to those with widely varying pathologies
(263 of which were studied by us and gave a signifi-
cative image), it is important to know the percentage
of samples for each instrument that are submitted to
microscopic control. If we consider both the distri-
butional and the morphological abnormalities pro-
duced by the instruments, this percentage varies from
27.4% (HI and NE 8000) (a similar percentage has
been published for HI (27)), to 27.0% (STKS) to
36.9% (CD 3000). Whenever the distributional ab-
normalities are not taken into consideration (and this
could be justified by the high level of accuracy and
precision in the count of these analysers), this per-
centage varies from 12.9% (NE 8000) to 17.1%
(STKS) to 19% (HI) to 27.4% (CD 3000). However,
this last approach must be used with caution, because
it risks the exclusion of a reasonable number of sam-
ples from the microscopic examination (from 2.2%
for the HI, to 3.4% for the STKS and CD 3000, to
6.4% for the NE 8000), in which the distributional
abnormality hides a morphological abnormality that
is not revealed by the instrument. In conclusion, we~
can say that the microscopic research, though not
totally replaceable by any haematological analyser, is
being widely redimensioned, because it is limited to
those samples which have count abnormalities or are
accompanied by distributional or morphological
flags.
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for Hepatitis B Surface Antigen and Hepatitis B Core IgM Class Antibody
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Participants
The following institutions were advised to perform tests on clinical samples according to the procedure
described in the "Design of the Studies" section:
Participants in the HBsAG assay
Community Blood Center of Greater Kansas City (Kansas City/USA), supervisor: G. Tegtmeier,
Baylor College of Medicine (Houston/USA), supervisor: B. Hollinger and C. Troisi,
Continental Services Group Inc. (Miami/USA), supervisor: F. de Velasco,
North American Biological Inc. (Miami/USA), supervisor: D. Hutchinson.
Participants in the anti-HBc assay
Community Blood Center of Greater Kansas City (Kansas City/USA) (a) supervisor: G. Tegtmeier,
University of Miami (USA), supervisor: E. Schiff,
Boston Biomedica Inc. (West Bridgewater/USA), supervisor: P. E. Garreit,
Cliniques Universitaires St. Luc (Brussels/Belgium), supervisor: M. E. Lamy.
(Received July 13/ November 16, 1992)
Summary: Two new monoclonal antibody-based automated enzyme immunoassays for hepatitis B markers
were tested for their clinical performance. The assays specifically detect hepatitis B surface antigen (HBsAg)
and* hepatitis B core (HBc) IgM antibodies by radial partition fluorescence enzyme immunoassay.
Taken together, the HBsAg and IgM anti-HBc assay show clinical sensitivities of 99.5% and 95.6% and
respective clinical specificities of 99.8% and 99.5%, compared with standard ELISAs. The detection limit
goes down to 50 PEI units per litre for HBsAg ad subtype and 70 PEI units per litre for ay subtype.
Introduction
Hepatitis B virus (HBV1) is an enveloped partially
double-stranded DNA virus belonging to the recently
l) Abbreviations:
HBV = hepatitis B virus;
HBsAg = hepatitis surface antigen;
HBcAg = hepatitis core antigen;
Anti-HBc = antibody against HBcAg;
HDV = hepatitis Delta vims;
FDA = Federal Drug Administration;
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designated group of Hepadnaviridae (1). More than a
quarter of a billion people worldwide carry the virus,
which is a leading cause of liver cancer (2). The
FN = false negative;
FP = false positive;
rDNA = recombinant DNA;
TN = true negative;
TP = true positive;
PEI = Paul-Ehrlich Institute.
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number of casualties is estimated to 2 millions a year
(3). The virion (Dane particle) is 42 nm in diameter
and its nucleocapsid 27 nm. The core has an icosa-
hedral form, built up of 180 copies of a 22000 Mr
core protein termed HBcAg. A truncated core protein
has different antigenicity and is named HBeAg (4, 5).
The lipid bilayer envelope surrounding the core con-
tains the complex antigen determinant called HBsAg
(Australia, surface, hepatitis associated antigen),
which is composed of carbohydrates, lipids and var-
ious proteins. Antigenic subtyping of HBsAg revealed
one common determinant to all HBsAg, termed a,
and two sets of determinants which mutually exclude
each other, namely d or y and w or r. This gives the
possible four subtypes: adw, adr, ayw and ayr (6).
HBsAg is the first detectable immunoserological
marker in the course of a hepatitis B virus infection
(7) and a marker of both acute and chronic hepatitis
B (8). It usually appears some weeks prior to the onset
of hepatitis symptoms, but is cleared quickly in re-
covering patients. The core antigen (HBcAg) of hep-
atitis B virus cannot be detected directly since it is
masked by the viral envelope, whereas HBeAg can be
found in the blood stream. The antibody elicited
against HBcAg is another useful marker. IgM anti-
HBc has been detected at high concentrations in acute
hepatitis B (9,10) and lower concentrations in chronic
hepatitis B (11-15). IgM anti-HBc finds its para-
mount diagnostic role as a reliable marker for acute
hepatitis B infection. Since HBsAg and HBeAg are
often cleared quickly (9,10,16), IgM anti-HBc covers
the diagnostic gap between the disappearance of
HBsAg and HBeAg and the appearance of anti-
HBsAg and anti-HBeAg antibodies (the so-called core
window) (17).
Materials and Methods
The Stratus® IgM anti-HBc and HBsAg assays are rapid qual-
itative automated procedures intended for use with the Stratus®
analysers II and Ilntellect (for review of the machines see 1. c.
(18)). The immunoassay format used is a sandwich method.
Both, analyser and kits are manufactured by Baxter Diagnostics
Incorporated, Miami, FLA, USA.
For the surface antigen assay, the clinical sample (100 out of
250 μΐ, either serum or plasma) is pipetted onto the centre
portion of a square of glass fibre paper containing pre-immo-
bilized (by complexation with goat anti- IgG Fc mouse anti-
bodies) murine monoclonal antibodies against HBsAg. If
HBsAg is present in the sample, binding to this antibody will
occur. A different murine monoclonal anti-HBsAg antibody
(IgG Fab' fragment) (30 μΐ) covalently linked to calf intestine
alkaline phosphatase is left to react with the bound HBsAg.
Application of a substrate/wash solution (1 mmol/1 Φ-methyl-
umbelliferyl phosphate in 63 g/1 diethanolamine buffer pH 9)
(20 and 50 ul in two increments) to the centre of the reaction
zone results in the migration of unbound conjugate and serum/
plasma components away from the reaction centre by radial
elution. The fluorogenic reaction is initiated at the same time
and measured kinetically via front surface fluorescence. The
excitation wavelength is 365 nm and emission is measured at
450 nm. The data analysis is performed by the microprocessor
within the analyser (19). The analyser transforms the optical
(fluorescence) signal into quantitative' hiV-readings (mV/min),
which are used to report qualitative results, either non-reactive,
reactive or highly reactive. Relative reactivity is based on the
comparison of sample millivolts to a cut-off value, calculated
from the millivolt readings of the 2 positive and 3 negative
controls. The negative controls are processed human plasma
containing 1 g/1 sodium azide. The positive controls are vaccine-
grade human plasma-derived hepatitis Β surface antigen in a
Tris/HCl (pH 7.8) buffer containing: 8.5 g/1 sodium chloride,
10 ml/1 Brij 35, 0.2 g/1 chloramphenicol, 1 ml/1 of 4rng/l clo-
trimazole in methanol, 7 g/1 hydrochloric acid, 80 g/1 bovine
serum albumin and 1 g/1 sodium azide.
The CV tolerance for the positive controls is set at g 5%, and
for the negative controls at <£ 12%. The ratio of the average
value of the positive controls to the average value of the negative
controls must be > 6.5. If all these criteria are met, the analyser
calculates a cut-off (mV/min) using the formula:
Cut-off (mV/min) = (x pos. control — χ neg. control)Κ
Η- χ neg. control
with Κ being determined for each kit lot to account for lot-to-
lot variations. It is determined by running 1000 negative sam-
ples per lot to:
χ pos. controls — χ neg. controls
(x 1000 neg. controls + 4 SD) — χ neg. controls
with η (χ pos. controls) = 90 and η (χ neg. controls) = 120.
The K-value is determined for each lot by the manufacturer.
Samples below the cut-off are classified non-reactive and sam-
ples above as reactive. The cut-off is normally situated at about
300 mV/min. Samples yielding values higher then 17000 mV/
min are referred to as highly reactive.
In accordance with an FDA protocol recommendation for
HBsAg, specimens non-reactive with Stratus® and the chosen
reference are considered negative for HBsAg and need no re-
testing. Specimens demonstrating reactivity for HBsAg by Stra-
tus® and/or the reference method are re-analysed in duplicate
using either of the two methods. If both replicates are non-
reactive in the repeat test, the specimen is considered non-
reactive by that method. However, if one or both of the repli-
cates are reactive in the repeat test, the specimen is considered
reactive for HBsAg by that method. Specimens that are re-
peatedly reactive (in initial result and repeat result) by one or
both methods are confirmed using the confirmatory test for
that method (see fig. 1 for a complete outline of the procedure).
Thus, the result of the confirmation test determines the final
classification. If the confirmatory tests for one sample disagree
for Stratus® and the reference method, this sample is referred
to as false positive or false negative compared with the result
of the reference confirmatory test (see fig. 1, cohinin: final vs.
final). The confirmation test for Stratus® HBsAg-assay uses
human polyclonal HBsAg antibody to neutralize hepatitis B
surface antigen detected in screened reactive and highly reactive
samples. Screened positive samples which can be neutralized
are confirmed positive, while those which cannot be neutralized
are considered false-positive. In the confirmatory assay, a sam-
ple aliquot (in the case of highly reactive samples diluted 1/50)
is mixed with a negative diluent (equine serum) and with the
polyclonal anti-HBsAg antibodies in parallel. If HBsAg is pres-
ent in the sample, it will be partially removed by the complex-
ation with the polyclonal antibodies. 'Each aliquot is then added
to a tab which contains pre-immobilized monoclonal murine
anti-HBsAg as described above. The aliquot which has been
premixed with only negative diluent contains uncomplexed an-
Eur. J. Clin. Chem. Clin. Biochem. / Vol. 31,1993 / No. 4
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tigens which readily bind to available sites on the glass fibre
paper tab. This bound antigen is then detected as already
described. Samples containing HBsAg and neutralized aliquots
show a significantly lower rate of bound conjugate activity than
aliquots premixed with negative diluent, whereas HBsAg-neg-
ative samples show no difference at all. Reactive samples are
considered confirmed if neutralized aliquots show a minimum
of 15% reduction in mV/min readings as compared with sam-
ples treated with negative diluent. Highly reactive samples have
to show at least a 25% reduction.
For the IgM anti-HBc antibody assay, the clinical sample (200
μ!) is first automatically diluted 1/625 in sample and positive
control diluent (1 g/1 gelatine, 20 g/1 bovine serum albumin, 150
mmol/1 sodium chloride, 1 g/1 sodium azide, 1 g/1 surfactant in
100 mmol/1 Tris/HCl buffer pH 7.6) to exclude possible hook
effects (20). IgM present in the sample reacts with a raurine
monoclonal anti human μ chain antibody immobilized as de-
scribed above on the tab. Recombinant hepatitis Β core antigen
(rDNA HBcAg) is applied in solution (40 μΐ) (composition: 30
g/I bovine serum albumin, 150 mraol/1 NaCl, 50 ml/1 Tween-
20, 1 g/1 sodium azide, 100 mmol/1 Tris/pH 7.6) forming a
sandwich with core-specific IgM antibody which might be pres-
ent in the sample. In addition, this step removes unbound serum
or plasma components from the centre of the tab by radial
elution. A murine monoclonal anti-HBc antibody covalently
linked to calf intestine alkaline phosphatase in Stratus® con-
jugate diluent (40 μΐ) is then added. The formation of the
complex is then detected as described above.
As with the surface antigen test, quantitative mV/min data are
converted into qualitative results, either as non-reactive, reac-
tive or for re-test. Relative reactivity is based on the comparison
of sample millivolts with a cut-off value, calculated from the
millivolt readings of the 2 positive and 2 negative controls. The
positive controls must lie between 3300 and 6300 mV/min and
the negative below 300 mV/min. If these criteria are met, the
analyser calculates a cut-off value as follows:
Cut-off (mV/min) = (x pos. control - χ neg. control)
χ Κ + x neg. control
with Κ being a kit lot-specific constant with
χ cut-off reference prep. — χ neg. controliv = ·—·
χ pos. control — χ neg. control
The χ cut-off value of the reference preparation is the averaged
mV/min readings of a preparation of 60 000 PEI units IgM
anti-HBc per litre (n (x cut-off) = 50, η (χ neg. controls) = 15,
n(x pos. control) = 15). Both the x cut-off of the reference
preparation and the K-value are determined for each lot by the
manufacturer.
Patient samples that read > 10% above this cut-off value are
reported reactive. Samples g 10% below are considered non-
reactive. Patient readings between those limits are reported as
re-test. If patient results consistently report as re-test, the status
of the patient is to be considered as borderline and should be
constantly monitored.
Pipetting and incubation steps with the Stratus® automated
analysers are executed in a couple of minutes, so that first
results are at hand after 12 minutes for the monoclonal HBsAg
and 13 minutes for the monoclonal IgM anti-HBc assay.
Sample 'storage
Plasma and serum samples obtained in vacutainers were tested
immediately or stored at 4 °C for a maximum of one week.
Specimens stored for a longer period were kept frozen at
-20°C.
Design of the Studies
All external participants went through a familarization phase
with the analyser so s to assure the correct use of the equip-
ment. ,
 f
Thereafter, 4 kinds of trials were performed:
First, for clinical specificity testing, serum and plasma from
apparently healthy donors were analysed for HBsAg according
to the FDA protocol outlined above with Auszyme® mono-
clonal, using its corresponding confirmation test (Abbott Lab-
oratories, North Chicago, IL) as the reference method. In
addition, a simple comparison was made between Stratus® and
Corzyme®-M (procedure A) (Abbott Laboratories, North Chi-
cago, IL) on healthy blood donors for the determination of
IgM anti-HBc.
Second, clinical sensitivity was established by comparing serum
or plasma from acute HBV patients in the IgM anti-HBc assay,
and from acute HBV patients, chronic HBsAg carriers and
patients infected with HDV (implicates co- or superinfection
with HBV) in the HBsAg-assay, using the above reference
methods.
Third, clinical specificity for various potentially interfering dis=
eases was determined again in comparison with the reference
methodology.
Fourth, chronic HBV carriers were tested with the Stratus® IgM
anti-HBc assay and with Corzyme-M®, in order to test the
claim of both assays for detection of acute hepatitis.
and discordance forDefinitions of concordance
HBsAg assay (see also fig. 1)
1. Specimens that are initially non-reactive by both methods
or are non-reactive by both methods after repeat testing are
concordant (true negative = TN).
2. Specimens that are repeatedly reactive by both methods are
concordant (true positive = TP).
3. Specimens that are repeatedly reactive by Stratus® and re-
peatedly non-reactive by the reference method are discordant
and defined false positive = FP.
4. Specimens that are repeatedly non-reactive by Stratus® and
repeatedly reactive by the reference method are also discor-
dant and defined false negative = FN.
Definitions of concordance and discordance for IgM
anti-HBc assay
1. Specimens that are initially non-reactive by both methods
are concordant (true negative = TN).
2. Specimens that are reactive by both methods are concordant
(true positive = TP).
3. Specimens that are reactive by Stratus® and non-reactive by
the reference method are discordant and defined false posi-
tive = FP.
4. Specimens that are non-reactive by Stratus® and reactive by
the reference method are also discordant and defined false
negative = FN.
5. If the Stratus® and/or the reference method result is "re-
test", the results are not used for statistical analysis.
Statistical analysis * ?
Clinical sensitivity in %: TP/(TP + FN) x 100
Clinical specificity in %: TN/(TN + FP) x 100
Eur. J. Clin. Chem. Clin. Biochern. / Vol. 31,1993 / No. 4
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Tab. 1. Detection of purified HBsAg ay and ad subtypes by Stratus® HBsAg assay.
HBsAg subtype ay
(103 U/l)
mV/min > cut-off HBsAg subtype ad
(103 U/l)
mV/min > cut-off
10
5
2.5
1
0.5
0.25
0.1
0.07
0.05
0.03
10065.9
5732.0
3097.5
1242.0
625.5
251.6
50.8
15.7
-7.3
-44.7
10
5
2.5
1
0.5
0.25
0.10
0.07
0.05
0.03
12800.4
6871.4
3661.7
1575.8
751.4
331.3
92.0
36.0
9.0
-22.9
Results are expressed in mV/min above the cut-off value thus specifying the limit of detection as the last concentration with
average values above the cut-off (n = 18 for each concentration)
Results
Detectability
In an in-house study, a limit of detection of the HBsAg
assay was determined by serial dilution of the Paul-
Ehrlich-Institute standards for HBsAg subtypes ad
and ay in the following manner. A half-logarithmic
dilution of either standard was tested with the Stra-
tus® HBsAg assay. The limit of detection was referred
to as the dilution at which the measured mV/min are
still above the cut-off value. Each subtype dilution
was tested 3 times in duplicate for three different
HBsAg assay lots and the average mV/min readings
calculated. The detection limit of ay subtype was
determined as 70 PEI units per litre and as 50 PEI
units per litre for ad subtype (tab. 1).
Clinical specificity
Table 2 shows the results of the specificity studies for
the Stratus® HBsAg assay at each of the different
trial sites. The resulting overall clinical specificity was
6384/6418 = 99.5%.
Clinical specificity data for the IgM core assay are
consolidated in table 3. The resultant overall clinical
specificity was 534/536 = 99.5%.
Clinical sensitivity
Table 4 gives the results of the sensitivity studies at
each trial site for HBsAg. Overall clinical sensitivity
is 681/686 =* 99.3%.
Clinical sensitivity data for the IgM core assay are
depicted in table 5; the overall clinical sensitivity was
226/237 = 95.6%.
Tab. 2. Clinical specificity data for HBsAg from each trial
centre
TN
FP
TN/(TN + FP)
Blood
Centre
Kansas
1977
27
98.7%
Baylor
College
104
0
100%
Conti-
nental
2305
5
99.8%
North
American
Biological
1998
2
99.9%
Tab. 3. Clinical specificity data for IgM anti-HBc from each
trial site
TN
FP
TN/(TN + FP)
Blood Centre
Kansas
499
1
99.8%
Cliniques
St. Luc
35
1*
97.2%
* patient with persistent hepatitis B (HBsAg and HBcAg pos-
itive)
Tab. 4. Clinical sensitivity data for HBsAg from each trial site
TP
FN
TP/(TP + FN)
Blood
Centre
Kansas
312
1
99.7%
Baylor
College
271
3
98.9%
North
American
Biological
98
1
99.0%
Tab. 5. Clinical sensitivity data for IgM anti-HBc for each test
centre
TP
FN
TP/(TP + FN)
Blood
Centre
42
5
89.7%
Miami
University
109
3
97.3%
Boston
Biomedica
75
3
96.2%
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Interferences
Samples belonging to various disease states or poten-
tial interference risk categories were tested for HBsAg
and IgM anti-HBc by both methods (tabs. 6 and 7).
HBsAg testing according to the outlined protocol of
table 1 identified 15 false positives out of a total of
421 negative reference samples, yielding the clinical
interference specificity of 421/436 = 96.6% (tab. 6).
IgM anti-HBc (tab. 7) attained a clinical interference
specificity of 425/425 = 100%, since there was only
one false negative and no false positive.
Specificity for the discrimination between
acute and chronic hepatitis B by IgM anti-
HBc assays
Both the Stratus® and the reference method claim to
detect acute hepatitis B. When only samples from
chronic carriers were examined, the Stratus IgM anti-
HBc indicated only 1 patient out of 203 as positive
for acute hepatitis B, whereas the Corzyme® mis-
matched 9 chronic patients into the category of acute
hepatitis B (tab. 8).
Discussion
Comparison between the Stratus® HBsAg (screen and
confirmatory) assay and the Stratus® IgM anti-HBc
assay with a reference ELISA yielded good clinical
sensitivity and specificity. If interference specificity
(tabs. 6 and 7) is taken into account for calculation
of clinical specificity, the following values are ob-
tained:
HBsAg: 6805/6854 = 99.3%,
IgM anti-HBc: 959/961 ** 99.8%.
Clinical sensitivity of the HBsAg assay lies at 99.5%
with a limit of detection clearly below 100 PEI units
per litre. Only the clinical sensitivity of the IgM anti-
HBc assay lies below 99% (95.6%), if compared with
the reference method. However, IgM anti-HB core is
an analyte whose sensitivity might best be calibrated
by its correlation to the clinical course of infection
and not by searching for a low limit of detection. The
core IgM test is used clinically to distinguish acute
from chronic or from convalescent infection. In most
of the clinical cases it is not necessary to detect ex-
tremely low levels of IgM anti-HBc, which may persist
Tab. 6. Clinical specificity data for potentially interfering samples (HBsAg-assay)
Blood Centre/Kansas and Baylor College
— compiled data from tests carried out at
Stratus® Reference method
Nega- Posi- Repeatedly Confirmed
tive live positive positive
Nega- Posi- Repeatedly Confirmed
tive tive positive positive
Convalescent HBV infection
Non-A/Non-B hepatitis
Acute HAV* infection
Other liver diseases**
Cirrhosis
Rheumatoid factor positive
Systemic lupus erythematosus
Anti-nuclear antibodies
Acute Epsiein-Barr virus infection
Acute Cytomegalovirus infection
Renal dialysis
Multiparous women
Multiply transfused patients
Malignancies
Intravenous drug abusers
Herpes simplex virus infection
Male homosexuals
HIV infection
Haemophiliacs
Rubella virus infection
Syphilis
Toxoplasmosis
93
11
15
13
12
9
8
9
7
7
15
19
23
• 24
23
10
27
6
29
11
10
10
7
0
5
2
0
1
2
1
3
3
5
1
0
1
2
0
3
4
3
0
0
0
2
0
1
2
0
0
1
0
3
0
3
1
0
1
2
0
3
2
1
0
0
0
1
0
0
1
0
0
0
0
3
0
0
0
0
0
0
0
2
0
0
0
0
* 0
99
11
20
14
11
10
10
10
7
10
20
10
23
25
25
10
27
8
30
11
10
10
1
0
0
1
1
0
0
0
3
0
0
0
0
0
0
0
3
2
2
0
0
0
0
0
0
1
0
0
0
0
3
0
0
0
0
0
0
0
3
0
0
0
0
0
0
0
0
1
0
0
0
0
3
0
0
0
0
0
0
0
1
1
0
0
0
0
Total 391 43 22 421 13
* hepatitis A virus
** cholestasis, hepatomegaly, hepatic encephalopathy, hepatoma etc.
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Tab. 7. Clinical specificity data for potentially interfering samples (IgM anti-HBc-assay) — compiled data from tests carried out
at Blood Centre/Kansas, Miami University and Boston Biomedica
Convalescent HBV infection
Hepatitis Delta infection
Non-A/Non-B hepatitis
Acute HAV* infection
Other liver diseases**
Cirrhosis
Rheumatoid factor positive
Systemic lupus erythematosus
Anti-nuclear antibodies
Acute Epstein- Bar r virus infection
Acute Cytomegalovirus infection
Renal dialysis
Multiparous women
Multiply transfused patients
Malignancies
Intravenous drug abusers
Herpes simplex virus infection
Male homosexuals
HIV infection
Haemophiliacs
Rubella virus infection
Syphilis
Toxoplasmosis
Stratus®
Negative
54
10
12
26
20
11
10
10
20
26
20
20
20
25
20
25
10
23
9
25
10
10
10
Reference method
Re-test
0
1
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
1
0
0
0
0
Positive
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
2
0
0
0
0
0
Negative
54
10
12
26
20
11
10
10
20
26
20
20
20
25
20
25
10
22
10
25
9
10
10
Re-test
0
1
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
1
0
0
Positive
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
3
0
0
0
0
0
Total 426 425
* hepatitis A virus
** cholestasis, hepatomegaly, hepatic encephalopathy, hepatoma etc.
Tab. 8. Acute hepatitis B test (IgM anti-HBc); results of chronic hepatitis B carrier samples
Stratus® Reference method
Negative Re-test Positive Negative Re-test
Total 199 192
Positive
Blood Centre/Kansas
Miami University
Boston Biomedica
101
23
75
0
3
0
0
1
0
98
20
74
0
1
1
3
6
0
long into convalescence or chronic infections. It is
more important to see the spike of IgM occurring at
the end of the acute phase. Therefore, it is interesting
to note that the Stratus^ IgM core recognizes only
one out of 203 chronic carrier samples as positive,
whereas the reference method gives 9 positive results
(tab. 8), probably due to detection of trailing IgM
anti-HBc.
In conclusion, both new third generation immuno-
assays (Stratus® HBsAg and IgM anti-HBc) are di-
agnostic tests for hepatitis B well adapted to the
clinical needs. Compared with the traditional ELISA,
they offer the advantage of complete automation of
the workflow, including print-out of results, built-in
control routines, and finally a significantly higher
speed.
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